Skip to main content

Advertisement

SpringerLink
Log in

Clinical Management of Episodic Memory Changes in Dementia

  • Dementia (J Pillai, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

The purpose of this review was to discuss therapeutic options available for the treatment of memory difficulties in dementia.

Recent findings

Because of the lack of progress in the availability of new medications, there has been an increased interest in focusing on non-pharmacological means to management cognitive symptoms related to dementia.

Summary

The clinical management of memory loss should focus both on pharmacological and non-pharmacological approaches. Treatment with medications should usually begin with a cholinesterase inhibitor and then followed by addition of memantine if there is a decline. In addition to medication management, emphasis should be placed on the importance of maintaining a healthy lifestyle that encompasses physical activities, cognitive stimulation, and a healthy diet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. American Psychiatric Association, American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013.

  2. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2017. 2017;13(3):325–73.

  3. Budson AE, Price BH. Memory dysfunction. NEJM. 2005;352:692–9.

    Article  CAS  PubMed  Google Scholar 

  4. Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55(6):815–28.

    Article  CAS  PubMed  Google Scholar 

  5. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122–6.

    Article  CAS  PubMed  Google Scholar 

  6. Villarroya M, García AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer’s disease. Curr Pharm Des 2004;10(25):3177–3184.

  7. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.

    Google Scholar 

  8. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhu CW, Livote EE, Scarmeas N, Albert M, Brandt J, Blacker D, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer’s disease. Alzheimers Dement. 2013;9(6):733–40.

  10. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc. 2003 Jul;51(7):937–44.

    Article  PubMed  Google Scholar 

  11. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009 May;24(5):479–88.

  12. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004 Jun 26;363(9427):2105–15.

    Article  CAS  PubMed  Google Scholar 

  13. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015 Dec;14(12):1171–81.

    Article  PubMed  Google Scholar 

  14. Alva G, Cummings JL. Relative tolerability of Alzheimer’s disease treatments. Psychiatry (Edgmont). 2008;5(11):27–36.

    Google Scholar 

  15. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707–14.

    Article  PubMed  Google Scholar 

  16. Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer’s disease. Curr Med Res Opin. 2005;21(11):1809–18.

  17. O’Regan J, Lanctôt KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015 Nov;76(11):e1424–31.

    Article  PubMed  Google Scholar 

  18. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003 Fall;9(3):275–308.

    Article  CAS  PubMed  Google Scholar 

  19. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61–74.

    CAS  PubMed  Google Scholar 

  20. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006 19;(2):CD003154.

  21. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32–8.

    Article  PubMed  Google Scholar 

  22. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–24.

    Article  CAS  PubMed  Google Scholar 

  23. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):263–8.

    Article  CAS  PubMed  Google Scholar 

  24. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83–9.

    Article  CAS  PubMed  Google Scholar 

  25. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6. https://doi.org/10.1186/alzrt160. eCollection 2013. This meta-analysis supports the use of combination therapy of cholinesterase inhibitor and memantine.

  26. Davenport MH, Hogan DB, Eskes GA, Longman RS, Poulin MJ. Cerebrovascular reserve: the link between fitness and cognitive function? Exerc Sport Sci Rev. 2012;40(3):153–8.

    PubMed  Google Scholar 

  27. Erickson KI, Weinstein AM, Lopez OL. Physical activity, brain plasticity, and Alzheimer’s disease. Arch Med Res. 2012;43(8):615–21.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Raji CA, Merrill DA, Eyre H, Mallam S, Torosyan N, Erickson KI, et al. Longitudinal relationships between caloric expenditure and gray Matter in the Cardiovascular Health Study. J Alzheimers Dis. 2016;52(2):719–29.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Dougherty RJ, Schultz SA, Kirby TK, Boots EA, Oh JM, Edwards D, et al. Moderate physical activity is associated with cerebral glucose metabolism in adults at risk for Alzheimer’s Disease. J Alzheimers Dis. 2017;58(4):1089–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD006489. DOI: https://doi.org/10.1002/14651858.CD006489.pub4.

  31. Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer’s disease: a systematic review. Int Psychogeriatr. 2014;26(1):9–18.

    PubMed  Google Scholar 

  32. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD003260. DOI: https://doi.org/10.1002/14651858.CD003260.pub2.

  33. Buschert V, Bokde AL, Hampel H. Cognitive intervention in Alzheimer disease. Nat Rev. Neurol. 2010;6:508–17.

    Article  CAS  PubMed  Google Scholar 

  34. Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD005562. DOI: https://doi.org/10.1002/14651858.CD005562.pub2.

  35. Huntley JD, Gould RL, Liu K, Smith M, Howard RJ. Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open. 2015;5:e005247. https://doi.org/10.1136/bmjopen-2014-00524.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Graessel E, Stemmer R, Eichenseer B, et al. Non-pharmacological, multicomponent group therapy in patients with degenerative dementia: a 12-month randomizied, controlled trial. BMC Med. 2011 Dec 1;9:129. https://doi.org/10.1186/1741-7015-9-129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lauenroth A, Ioannidis AE, Teichmann B. Influence of combined physical and cognitive training on cognition: a systematic review. BMC Geriatr. 2016 Jul 18;16:141.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Shimada H, Makizako H, Doi T, Park H, Tsutsumimoto K, Verghese J, et al. Effects of combined physical and cognitive exercises on cognition and mobility in patients with mild cognitive impairment: a randomized clinical trial. J Am Med Dir Assoc. 2017 Nov 16. pii: S1525–8610(17)30542-X. doi: https://doi.org/10.1016/j.jamda.2017.09.019. This recent randomized clinical trial demonstrated benefits of combined physical and cognitive activities in cognition in subjects with mild cognitive impairment.

  39. Hardman RJ, Kennedy G, Macpherson H, Scholey AB, Pipingas A. Adherence to a Mediterranean-style diet and effects on cognition in adults: a qualitative evaluation and systematic review of longitudinal and prospective trials. Front Nutr. 2016;3:22. https://doi.org/10.3389/fnut.2016.00022. eCollection 2016

    Article  PubMed  PubMed Central  Google Scholar 

  40. • Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. Adv Nutr. 2016;7(5):889–904. This recent systemic review provides a good summary and overview of Mediterranean diet and cognition.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Gu Y, Brickman AM, Stern Y, Habeck CG, Razlighi QR, Luchsinger JA, et al. Mediterranean diet and brain structure in a multiethnic elderly cohort. Neurology. 2015;85(20):1744–51.

  42. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol. 2006;63(12):1709–17.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Widmer RJ, Flammer AJ, Lerman LO. Lerman A3. The Mediterranean diet, its components, and cardiovascular disease. Am J Med. 2015 Mar;128(3):229–38.

    Article  PubMed  Google Scholar 

  44. • Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63. https://doi.org/10.1016/S0140-6736(15)60461-5. This is one of the largest randomized controlled trial that showed a multimodal approach including diet, exercise, and cognitive stimulation could maintain or improve cognitive function in at risk subjects.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic Lou Ruvo Center for Brain Health, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA

    Po-Heng Tsai MD

Authors
  1. Po-Heng Tsai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Po-Heng Tsai MD.

Ethics declarations

Conflict of Interest

The author declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Dementia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsai, PH. Clinical Management of Episodic Memory Changes in Dementia. Curr Treat Options Neurol 20, 6 (2018). https://doi.org/10.1007/s11940-018-0491-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-018-0491-8

Keywords

Search

Navigation